通用中文 | 沙美特罗替卡松粉吸入剂 | 通用外文 | Salmeterol (as xinafoate) +Fluticasone propionate |
品牌中文 | 品牌外文 | Brequal Inhalation | |
其他名称 | 沙美特罗/丙酸氟替卡松 | ||
公司 | Abdi Ibrahim(Abdi Ibrahim) | 产地 | 土耳其(Turkey) |
含量 | 50mcg/500mcg | 包装 | 60粒/盒 |
剂型给药 | 储存 | 室温 | |
适用范围 | 哮喘 |
通用中文 | 沙美特罗替卡松粉吸入剂 |
通用外文 | Salmeterol (as xinafoate) +Fluticasone propionate |
品牌中文 | |
品牌外文 | Brequal Inhalation |
其他名称 | 沙美特罗/丙酸氟替卡松 |
公司 | Abdi Ibrahim(Abdi Ibrahim) |
产地 | 土耳其(Turkey) |
含量 | 50mcg/500mcg |
包装 | 60粒/盒 |
剂型给药 | |
储存 | 室温 |
适用范围 | 哮喘 |
简介:通用名称丙酸氟替卡松100mcg+沙美特罗50mcg药理分类:类固醇激素+长效β-2激动剂公司名称:葛兰素史克制药ADVAIR DISKUS 100/50 RxGeneric Name and Formulations:Fluticasone propionate 100mcg, salmeterol ( ...
关键字:丙酸氟替卡松/沙美特罗吸入剂 哮喘
通用名称
沙美特罗50mcg+丙酸氟替卡松250mcg
药理分类:
类固醇激素+长效β-2激动剂
ADVAIR DISKUS 100/50 Rx
Generic Name and Formulations:
Fluticasone propionate 100mcg, salmeterol (as xinafoate) 50mcg; per inh; dry pwd for inh.
Indications for ADVAIR DISKUS 100/50:
Maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, inhaled corticosteroid) or whose disease severity warrants initiation of 2 maintenance therapies.
Adult Dose for ADVAIR DISKUS 100/50:
Allow approximately 12hrs between doses. Asthma: ≥12yrs: not previously on inhaled steroid: 1 inh of 100/50 or 250/50 twice daily; already on inhaled steroid: see literature. If insufficient response after 2wks, use next higher strength. Max 1 inh of 500/50 twice daily. COPD: 1 inh of 250/50 twice daily. Rinse mouth after use.
Children's Dose for ADVAIR DISKUS 100/50:
<4yrs: not recommended. Allow approximately 12hrs between doses. Asthma: 4–11yrs: 1 inh of 100/50 twice daily. Rinse mouth after use.
See Also:
ADVAIR DISKUS 250/50
ADVAIR DISKUS 500/50
Pharmacological Class:
Steroid + long-acting beta-2 agonist.
Contraindications:
Primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures. Concomitant with other forms of salmeterol or formoterol. Severe milk protein hypersensitivity.
Warnings/Precautions:
Increased risk of asthma-related deaths and hospitalizations. Do not initiate in rapidly or acutely deteriorating asthma. Not for relief of acute bronchospasm. Not for use with other long-acting β2-agonists or for transferring from systemic steroids. Reevaluate periodically. Do not exceed recommended dose. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Hepatic impairment (monitor). Tuberculosis. Untreated infections. Ocular herpes simplex. Eosinophilic conditions. Immunosuppressed. If exposed to chickenpox or measles, consider immune globulin prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Monitor potassium, intraocular pressure; bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, discontinue gradually). Do not use with spacers. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
See Contraindications. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, atazanavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin): not recommended. Caution with other sympathomimetics (except short-acting bronchodilators), during or within 2 weeks of MAOIs, tricyclic antidepressants (increased cardiac effects), K+–depleting diuretics. Antagonized by β-blockers.
Adverse Reactions:
Upper respiratory tract infection or inflammation, pharyngitis, pneumonia, laryngeal spasm or swelling, headache, dizziness, hoarseness, dysphonia, sinusitis, pain, GI upset, oral candidiasis, bronchitis, cough, paradoxical bronchospasm (discontinue if occurs), musculoskeletal pain; rarely: serious asthma episode, asthma-related death. Children: also epistaxis.
How Supplied:
Diskus (60 blisters)—1
推荐用量为Advair的DISKUS
成人
Advair的DISKUS的推荐剂量是一个吸入,每日两次。以吸入早晨和傍晚,间隔12小时。
产品有三个优势。你的医生会为您选择最佳的强度,根据您目前的治疗。如果此选项不能改善你的症状,2周后,医生可能会开一个更高的强度。
儿童
12岁及以上青少年Advair的的DISKUS可以使用。为成人的剂量是相同的。
Advair的DISKUS有时可以用于控制哮喘儿童的年龄在4至11岁的。为了让这些孩子中,只有最低强度的药物。
Advair的DISKUS不应该被用于4岁以下的儿童。
【药物过量】
任何药物摄取过量,可能会产生严重的后果。如果您怀疑服用过量,请立即就医。
急性Advair的DISKUS过量的症状可能包括:
快速或不规则的心跳,头痛,肌肉痉挛,震颤